 CORAL GABLES, Fla., Oct. 4, 2021 PRNewswire -- Relmada Therapeutics, Inc. NASDAQ: RLMD, a late-stage biotechnology company addressing diseases of the central nervous system CNS, today provided regulatory and development updates regarding its ongoing late-stage clinical program for REL-1017 in major depressive disorder MDD. 